Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of KVD824 for long-term prophylaxis in hereditary angioedema type I or II
2021-000136-59Phase 2Terminated
- Sponsor
- KalVista Pharmaceuticals
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KVD824 in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2) (4 arms), sponsored by KalVista Pharmaceuticals. Started Jul 2021; status: terminated.
02
Drugs
KVD824
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on 2021-000136-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000136-59.